Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-8954 · 1 trial · 1 indication
the number of subjects reporting adverse events by treatment group
Number of subjects with retention less than 13% at 180 minutes after dosing.
| Arm | Type | Description |
|---|---|---|
| TD-8954 | EXPERIMENTAL | TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours |
| Metoclopramide | ACTIVE_COMPARATOR | Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline |
| Name | Type | Description |
|---|---|---|
| TD-8954 | DRUG | - |
| Metoclopramide | DRUG | - |
Inclusion Criteria: * Intubated, on mechanical ventilation, and anticipated to remain on mechanical ventilation for 2 days after enrollment into the study * Receiving enteral feeding and assessed to have developed EFI, as defined by a GRV measurement ≥250 mL within the 24 hours before randomization...
TD-8954 is an investigational small molecule being developed for enteral feeding intolerance, a gastrointestinal condition in critically ill patients who cannot tolerate tube feeding. It is administered intravenously and is currently in Phase 1 clinical development.
TD-8954 is a small molecule designed to address enteral feeding intolerance, but its specific molecular target has not been disclosed. It is being studied for its pharmacodynamic effects in critically ill patients, though the exact mechanism of action is not publicly detailed.
TD-8954 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company headquartered in Japan. Takeda is listed on the stock exchange under the ticker symbol TAK.
TD-8954 is in Phase 1 clinical development. It has completed one Phase 1 trial, and it remains an investigational drug that has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated in clinical studies.
TD-8954 has been studied in one completed Phase 1 clinical trial, identified as NCT01953081. This randomized, double-blind, active-controlled study evaluated a single intravenous dose of TD-8954 compared with metoclopramide in 13 critically ill patients with enteral feeding intolerance in Australia.
No, TD-8954 is not the same as metoclopramide. Metoclopramide is an existing medication used as an active comparator in the clinical trial of TD-8954, which is an investigational drug being studied for enteral feeding intolerance. They are distinct compounds.